Vizient, Inc. Urges CMS to Reconsider 340B & “Site-Neutral” Policies in Proposed OPPS Rule




IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. is disappointed with the recently released Centers for Medicare and Medicaid Services (CMS) annual outpatient prospective payment system (OPPS) proposed rule, specifically those policies related to the 340B Drug Pricing Program and “site-neutral” payments.

The 340B Program is critical to America’s safety net, allowing hospitals to provide lifesaving programs to the nation’s most vulnerable patients and communities. CMS is proposing to deepen last year’s damaging cuts to 340B hospitals by extending them to an even greater number of hospital outpatient clinics. This policy will not serve to lower the cost of prescription drugs, but instead will only decrease access to care for the nation’s most vulnerable populations.

CMS has also proposed to continue harmful “site-neutral” payment cuts. These payment reductions will further reduce access to hospital-level outpatient care, especially in areas with already limited sources of health care. Patients across the nation rely on outpatient services provided by our member hospitals.

We urge CMS to reconsider both of these harmful proposals that only serve to negatively impact hospitals’ ability to provide high quality health care services and impede access to care.

Vizient is the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers.

About Vizient, Inc.

Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2018, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.


Vizient, Inc.
Angie Boliver, 972-830-7961

Related Materials